Results 1 to 10 of about 12,380 (135)
Multi-Omics Integration Uncovers That Tenofovir Disoproxil Fumarate Is Linked to Hepatic Metabolic Reprogramming Independent of Viral Infection [PDF]
LifeBackground and Aims: TDF is a first-line antiviral for CHB with pleiotropic effects including immunomodulation and fibrosis regression, but its virus-independent mechanisms are unclear. This study delineates TDF’s direct molecular and metabolic landscape
Yuanqin Duan +6 more
doaj +2 more sources
An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate [PDF]
Drugs in R&DBackground and Objectives The nucleoside reverse transcriptase inhibitors tenofovir alafenamide fumarate and tenofovir disoproxil fumarate are frequently employed in treating human immunodeficiency virus.
Derek E. Murrell +8 more
doaj +2 more sources
Comparative risk of osteoporosis and fractures in chronic hepatitis B patients: Tenofovir disoproxil fumarate vs. entecavir in a Korean nationwide cohort [PDF]
JHEP ReportsBackground & Aims: The optimal antiviral agent for patients with chronic hepatitis B (CHB) at risk for osteoporosis remains debated. The aim of this study was to compare the incidence of osteoporosis and osteoporotic fractures between patients ...
Yoon E. Shin +5 more
doaj +2 more sources
Tenofovir-induced osteopenia and hyperparathyroidism: A case report and literature review
Frontiers in Endocrinology, 2023 Tenofovir disoproxil fumarate is the first-line antiviral therapy for chronic viral hepatitis B, but long-term use is associated with renal failure and hypophosphatemic osteomalacia.
Jing Zeng +4 more
doaj +1 more source
The Turkish Journal of Gastroenterology, 2022 Background: We aimed to investigate the long-term effects of tenofovir disoproxil fumarate and entecavir treatment on bone mineral density and evaluated the fracture risk assessment tool score in patients with chronic hepatitis B.
Resul Kahraman +7 more
doaj +1 more source
Osteopenia in a young man associated with the use of tenofovir disoproxil fumarate
Clinical Case Reports, 2022 Tenofovir disoproxil fumarate is a recommended first‐line therapy for patients with chronic hepatitis B, although the frequent Tenofovir disoproxil fumarate related adverse drug reactions are nephrotoxicity and bone toxicity.
Chunmei Li, Hui Li, Ming Gong, Jia Wei
doaj +1 more source
Future Journal of Pharmaceutical Sciences, 2021 Background To establish a simple, sensitive, accurate, precise, efficient, economical RP-UPLC method for simultaneous estimation of Doravirine, Lamivudine and Tenofovir disoproxil fumarate in bulk and their combined pharmaceutical formulations ...
Swetha Addanki, B. Ramya Kuber
doaj +1 more source
Beni-Suef University Journal of Basic and Applied Sciences, 2022 Background A meta-analysis was made to assess the impact of entecavir comparison with tenofovir disoproxil fumarate as nucleos(t)ide analogue on hepatic cellular carcinoma (HCC). The study had subjects with chronic hepatitis B virus (HBV).
Sara M. Tony +3 more
doaj +1 more source
The Turkish Journal of Gastroenterology, 2022 Background: The effect of hepatic steatosis on the response to antiviral therapy administered in chronic hepatitis B patients is yet to be clarified. In this study, our aim was to determine the effect of hepatic steatosis on the virological response in ...
Roni Atalay +6 more
doaj +1 more source
Emtricitabine/Tenofovir Disoproxil Fumarate
Drugs in R & D, 2004 Gilead Sciences is developing a fixed-dose co-formulation of two of its reverse transcriptase inhibitors, emtricitabine [Emtriva] and tenofovir disoproxil fumarate [Viread], for once-daily dosing in combination with other antiretrovirals for the treatment of HIV infection.
Toni M, Dando, Antona J, Wagstaff
openaire +4 more sources